FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000557631> ?p ?o ?g. }

• W2000557631 endingPage "33" @default.
• W2000557631 startingPage "27" @default.
• W2000557631 abstract "To document whether c-erbB-2 over-expression or p53 accumulation in tumour cells was predictive of response to chemo- or radiotherapy, we analyzed a population of patients with breast cancer assigned to neo-adjuvant therapy (median follow-up: 54 months). T2/T3-N0N1b-M0 tumours (329 cases) were treated either by FAC chemotherapy or by radiotherapy before surgery, and the clinical response was classified as complete or incomplete. Expression of c-erbB-2 and p53 was retrospectively evaluated by immunohistochemistry. Proliferation rate was assessed by means of MIB-1 antibody and by S-phase fraction. A complete response to chemotherapy was observed in 38/167 patients (23%). Complete response rate was 20% in c-erbB-2-negative tumours, and rose to 31% in tumours with c-erbB-2 over-expression, but this trend was not statistically significant. There was no correlation between p53 staining and response to treatment, whereas chemosensitivity was found correlated with histological grade and S-phase. A complete response to radiotherapy was observed in 64 of the 156 evaluable patients (41%). Complete response rate was 41% in c-erbB-2- or p53-negative tumours, 54% in tumours with c-erb-B-2 over-expression, and 44% in tumours with p53 accumulation. There was no correlation between response to radiotherapy and histological grade or proliferative rate. No prognostic value was found for c-erbB-2 or p53 expression, whereas the 5-year survival rate was 85% for patients presenting a tumour with a low proliferating index (MIB-1 < 10%), and 68% for patients presenting a tumour with a high proliferative index. In multivariate analysis, node status (RR = 2), MIB-1 immunostaining (RR = 2), and tumour size (RR = 1.8) were found to be associated with survival. These results indicate that c-erbB-2 or p53 expression is not significantly associated with tumour response to neo-adjuvant chemo/radiotherapy in our series of breast cancers." @default.
• W2000557631 created "2016-06-24" @default.
• W2000557631 creator A5003776493 @default.
• W2000557631 creator A5012603842 @default.
• W2000557631 creator A5018736489 @default.
• W2000557631 creator A5019170401 @default.
• W2000557631 creator A5037340510 @default.
• W2000557631 creator A5044106072 @default.
• W2000557631 creator A5055974319 @default.
• W2000557631 creator A5056565799 @default.
• W2000557631 creator A5069238294 @default.
• W2000557631 creator A5073451431 @default.
• W2000557631 creator A5073631057 @default.
• W2000557631 creator A5074378026 @default.
• W2000557631 date "1998-02-20" @default.
• W2000557631 modified "2023-09-27" @default.
• W2000557631 title "No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer" @default.
• W2000557631 cites W119536604 @default.
• W2000557631 cites W1755920412 @default.
• W2000557631 cites W1786761502 @default.
• W2000557631 cites W1871768557 @default.
• W2000557631 cites W1925485320 @default.
• W2000557631 cites W1966268185 @default.
• W2000557631 cites W1983660791 @default.
• W2000557631 cites W2009269932 @default.
• W2000557631 cites W2015172444 @default.
• W2000557631 cites W2023576873 @default.
• W2000557631 cites W2025319947 @default.
• W2000557631 cites W2035318542 @default.
• W2000557631 cites W2050796903 @default.
• W2000557631 cites W2052193554 @default.
• W2000557631 cites W2053502729 @default.
• W2000557631 cites W2056851331 @default.
• W2000557631 cites W2061279941 @default.
• W2000557631 cites W2081894694 @default.
• W2000557631 cites W2086461593 @default.
• W2000557631 cites W2089889068 @default.
• W2000557631 cites W2096602429 @default.
• W2000557631 cites W2129936913 @default.
• W2000557631 cites W2328452031 @default.
• W2000557631 cites W4301025370 @default.
• W2000557631 doi "https://doi.org/10.1002/(sici)1097-0215(19980220)79:1<27::aid-ijc6>3.0.co;2-y" @default.
• W2000557631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9495354" @default.
• W2000557631 hasPublicationYear "1998" @default.
• W2000557631 type Work @default.
• W2000557631 sameAs 2000557631 @default.
• W2000557631 citedByCount "164" @default.
• W2000557631 countsByYear W20005576312012 @default.
• W2000557631 countsByYear W20005576312013 @default.
• W2000557631 countsByYear W20005576312015 @default.
• W2000557631 countsByYear W20005576312016 @default.
• W2000557631 countsByYear W20005576312020 @default.
• W2000557631 countsByYear W20005576312021 @default.
• W2000557631 countsByYear W20005576312022 @default.
• W2000557631 crossrefType "journal-article" @default.
• W2000557631 hasAuthorship W2000557631A5003776493 @default.
• W2000557631 hasAuthorship W2000557631A5012603842 @default.
• W2000557631 hasAuthorship W2000557631A5018736489 @default.
• W2000557631 hasAuthorship W2000557631A5019170401 @default.
• W2000557631 hasAuthorship W2000557631A5037340510 @default.
• W2000557631 hasAuthorship W2000557631A5044106072 @default.
• W2000557631 hasAuthorship W2000557631A5055974319 @default.
• W2000557631 hasAuthorship W2000557631A5056565799 @default.
• W2000557631 hasAuthorship W2000557631A5069238294 @default.
• W2000557631 hasAuthorship W2000557631A5073451431 @default.
• W2000557631 hasAuthorship W2000557631A5073631057 @default.
• W2000557631 hasAuthorship W2000557631A5074378026 @default.
• W2000557631 hasBestOaLocation W20005576311 @default.
• W2000557631 hasConcept C121608353 @default.
• W2000557631 hasConcept C126322002 @default.
• W2000557631 hasConcept C142724271 @default.
• W2000557631 hasConcept C143998085 @default.
• W2000557631 hasConcept C204232928 @default.
• W2000557631 hasConcept C2776694085 @default.
• W2000557631 hasConcept C2778001805 @default.
• W2000557631 hasConcept C509974204 @default.
• W2000557631 hasConcept C530470458 @default.
• W2000557631 hasConcept C71924100 @default.
• W2000557631 hasConceptScore W2000557631C121608353 @default.
• W2000557631 hasConceptScore W2000557631C126322002 @default.
• W2000557631 hasConceptScore W2000557631C142724271 @default.
• W2000557631 hasConceptScore W2000557631C143998085 @default.
• W2000557631 hasConceptScore W2000557631C204232928 @default.
• W2000557631 hasConceptScore W2000557631C2776694085 @default.
• W2000557631 hasConceptScore W2000557631C2778001805 @default.
• W2000557631 hasConceptScore W2000557631C509974204 @default.
• W2000557631 hasConceptScore W2000557631C530470458 @default.
• W2000557631 hasConceptScore W2000557631C71924100 @default.
• W2000557631 hasIssue "1" @default.
• W2000557631 hasLocation W20005576311 @default.
• W2000557631 hasLocation W20005576312 @default.
• W2000557631 hasOpenAccess W2000557631 @default.
• W2000557631 hasPrimaryLocation W20005576311 @default.
• W2000557631 hasRelatedWork W2348231456 @default.
• W2000557631 hasRelatedWork W2354050160 @default.
• W2000557631 hasRelatedWork W2367105124 @default.
• W2000557631 hasRelatedWork W2368979736 @default.
• W2000557631 hasRelatedWork W2369039771 @default.

• next